162 related articles for article (PubMed ID: 10827162)
21. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
22. Association between human leukocyte antigen class I and II alleles and hepatitis C virus infection in high-risk hemodialysis patients awaiting kidney transplantation.
Grimaldi V; Sommese L; Picascia A; Casamassimi A; Cacciatore F; Renda A; De Rosa P; Montesano ML; Sabia C; Fiorito C; De Iorio G; Napoli C
Hum Immunol; 2013 Dec; 74(12):1629-32. PubMed ID: 23974050
[TBL] [Abstract][Full Text] [Related]
23. Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation.
Shiffman ML; Stravitz RT; Contos MJ; Mills AS; Sterling RK; Luketic VA; Sanyal AJ; Cotterell A; Maluf D; Posner MP; Fisher RA
Liver Transpl; 2004 Oct; 10(10):1248-55. PubMed ID: 15376308
[TBL] [Abstract][Full Text] [Related]
24. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications.
Pradat P; Tillmann HL; Sauleda S; Braconier JH; Saracco G; Thursz M; Goldin R; Winkler R; Alberti A; Esteban JI; Hadziyannis S; Rizzetto M; Thomas H; Manns MP; Trepo C;
J Viral Hepat; 2007 Aug; 14(8):556-63. PubMed ID: 17650289
[TBL] [Abstract][Full Text] [Related]
25. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients.
Guo L; Orrego M; Rodriguez-Luna H; Balan V; Byrne T; Chopra K; Douglas DD; Harrison E; Moss A; Reddy KS; Williams JW; Rakela J; Mulligan D; Vargas HE
Liver Transpl; 2006 Apr; 12(4):560-5. PubMed ID: 16555313
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C etiology of liver disease is strongly associated with early acute rejection following liver transplantation.
McTaggart RA; Terrault NA; Vardanian AJ; Bostrom A; Feng S
Liver Transpl; 2004 Aug; 10(8):975-85. PubMed ID: 15390322
[TBL] [Abstract][Full Text] [Related]
27. HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis.
Zivadinov R; Uxa L; Bratina A; Bosco A; Srinivasaraghavan B; Minagar A; Ukmar M; Benedetto Sy; Zorzon M
Int Rev Neurobiol; 2007; 79():521-35. PubMed ID: 17531857
[TBL] [Abstract][Full Text] [Related]
28. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.
Testillano M; Fernandez JR; Suarez MJ; Gastaca M; Bustamante J; Pijoan JI; Montejo M; Valdivieso A; Ruiz P; Gonzalez J; Ortiz de Urbina J
Transplant Proc; 2009 Apr; 41(3):1041-3. PubMed ID: 19376421
[TBL] [Abstract][Full Text] [Related]
29. Human leukocyte antigen DR markers as predictors of progression to liver transplantation in patients with chronic hepatitis C.
Brandhagen DJ; Gross JB; Poterucha JJ; Germer JJ; Czaja AJ; Smith CI; Ribeiro AC; Guerrero RB; Therneau TM; Schiff E; Gordon FD; Wiesner RH; Persing DH
Am J Gastroenterol; 2000 Aug; 95(8):2056-60. PubMed ID: 10950057
[TBL] [Abstract][Full Text] [Related]
30. Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients.
Takada Y; Haga H; Ito T; Nabeshima M; Ogawa K; Kasahara M; Oike F; Ueda M; Egawa H; Tanaka K
Transplantation; 2006 Feb; 81(3):350-4. PubMed ID: 16477219
[TBL] [Abstract][Full Text] [Related]
31. Recurrent hepatitis C virus disease after liver transplantation and concurrent biliary tract complications: poor outcome.
Katz LH; Mor E; Brown M; Bar-Nathan N; Shaharabani E; Sulkes J; Pappo O; Tur-Kaspa R; Ben-Ari Z
Clin Transplant; 2006; 20(4):465-70. PubMed ID: 16842523
[TBL] [Abstract][Full Text] [Related]
32. HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C.
Romero-Gómez M; González-Escribano MF; Torres B; Barroso N; Montes-Cano MA; Sánchez-Muñoz D; Núñez-Roldan A; Aguilar-Reina J
Am J Gastroenterol; 2003 Jul; 98(7):1621-6. PubMed ID: 12873589
[TBL] [Abstract][Full Text] [Related]
33. Intra portal donor specific antigen transfusion might prevent re-infection of hepatitis C virus after living related liver transplantation in hepatitis C hepatic cirrhosis.
Sato Y; Oya H; Yamamoto S; Kobayashi T; Watanabe T; Kokai H; Yamagiwa S; Hatakeyama K
Hepatogastroenterology; 2009; 56(89):205-7. PubMed ID: 19453058
[TBL] [Abstract][Full Text] [Related]
34. The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation.
Mindikoglu AL; Regev A; Casanova-Romero PY; Bejarano PA; Martinez EJ; Tzakis AG; Schiff ER
Transplant Proc; 2006 Jun; 38(5):1440-4. PubMed ID: 16797327
[TBL] [Abstract][Full Text] [Related]
35. Association between human leukocytes antigen alleles and chronic hepatitis C virus infection in the Korean population.
Yoon SK; Han JY; Pyo CW; Yang JM; Jang JW; Kim CW; Chang UI; Bae SH; Choi JY; Chung KW; Sun HS; Choi HB; Kim TG
Liver Int; 2005 Dec; 25(6):1122-7. PubMed ID: 16343061
[TBL] [Abstract][Full Text] [Related]
36. Involvement of the fas system in hepatitis C virus recurrence after liver transplantation.
Crespo J; Rivero M; Mayorga M; Fabrega E; Casafont F; Gomez-Fleitas M; Pons-Romero F
Liver Transpl; 2000 Sep; 6(5):562-9. PubMed ID: 10980054
[TBL] [Abstract][Full Text] [Related]
37. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
Berenguer M; Aguilera V; Prieto M; San Juan F; Rayón JM; Benlloch S; Berenguer J
J Hepatol; 2006 Apr; 44(4):717-22. PubMed ID: 16487616
[TBL] [Abstract][Full Text] [Related]
38. Association of human leukocyte antigen polymorphism with outcomes of hepatitis B virus infection.
Ramezani A; Hasanjani Roshan MR; Kalantar E; Eslamifar A; Banifazl M; Taeb J; Aghakhani A; Gachkar L; Velayati AA
J Gastroenterol Hepatol; 2008 Nov; 23(11):1716-21. PubMed ID: 18761557
[TBL] [Abstract][Full Text] [Related]
39. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation.
Yilmaz N; Shiffman ML; Stravitz RT; Sterling RK; Luketic VA; Sanyal AJ; Mills AS; Contos MJ; Coterell A; Maluf D; Posner MP; Fisher RA
Liver Transpl; 2007 Jul; 13(7):975-83. PubMed ID: 17600360
[TBL] [Abstract][Full Text] [Related]
40. Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C.
López-Labrador FX; Berenguer M; Sempere A; Prieto M; Sirera R; González-Molina A; Ortiz V; Marty ML; Berenguer J; Gobernado M
Liver Transpl; 2004 Feb; 10(2):217-27. PubMed ID: 14762859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
